Hancock Whitney Corp Cuts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Hancock Whitney Corp decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 2.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,201 shares of the biotechnology company’s stock after selling 131 shares during the period. Hancock Whitney Corp’s holdings in United Therapeutics were worth $1,657,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. Meiji Yasuda Asset Management Co Ltd. increased its stake in shares of United Therapeutics by 1.6% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 33 shares during the last quarter. ClariVest Asset Management LLC grew its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after buying an additional 42 shares during the last quarter. Access Investment Management LLC raised its stake in shares of United Therapeutics by 0.8% in the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock valued at $2,314,000 after buying an additional 55 shares during the period. Finally, MBM Wealth Consultants LLC lifted its position in shares of United Therapeutics by 2.7% during the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after buying an additional 59 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $316.62, for a total transaction of $1,139,832.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $41,160.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $316.62, for a total transaction of $1,139,832.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $41,160.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 266 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the transaction, the director now owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,322 shares of company stock worth $35,403,906. 12.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. UBS Group boosted their price objective on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. LADENBURG THALM/SH SH cut shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. Bank of America lowered their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. Finally, Oppenheimer raised their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $350.36.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $353.00 on Monday. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The company has a market cap of $15.66 billion, a price-to-earnings ratio of 16.69, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08. The company has a 50-day moving average price of $339.19 and a 200-day moving average price of $292.07.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the business posted $5.24 EPS. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.86 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.